Affimed Therapeutics files Type F-1 registration statement designed for public offering of common stock Today announced that it offers filed a registration declaration on Form F-1 with the U Affimed Therapeutics.S. Securities and Exchange Commission relating to a proposed initial public offering of its common shares info . The number of shares to become offered and the purchase price range for the offering have not yet been determined. Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp.
Related StoriesImmune submits Bertilimumab IND application to FDA for treatment of Bullous PemphigoidHigh levels of satiety hormone leptin donate to coronary disease in obese individualsLatitude, summer time daylight exposure make difference in results for kids treated with growth hormone David Dodd, President and CEO of Aeterna Zentaris, commented, ‘The submission of the NDA to the FDA is certainly another major milestone inside our strategy to bring macimorelin acetate to advertise as the 1st approved oral item for AGHD evaluation.